Compare GSK plc (GSK) vs US Bancorp (USB) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

U.S. Bancorp (USB) trades at $63.87, up 2.78% with bullish technical signals and strong fundamentals. The stock shows consistent earnings beats (Q4 2025: $1.26 vs $1.19 expected; Q1 2026: $1.18 vs $1.14 expected) and record revenue growth driven by loan expansion and the BTIG acquisition. Analyst consensus is mixed with a $67 price target, while cash flow trends indicate strategic investments despite negative net flows. Recent news highlights robust Q2 2026 performance and new small business payment solutions.

Outlook remains positive with earnings momentum and dividend stability, though risks include interest rate sensitivity and elevated debt levels. The stock presents value at a P/E of 13.21, with upside potential if loan growth sustains. Key watchpoints are Q2 2026 earnings results and Federal Reserve policy impacts on net interest income.